Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) is estimated to be overexpressed in 60~80% of colorectal cancer (CRC), which is associated with a poor prognosis. Anti-EGFR targeted monoclonal antibodies (cetuximab and panitumumab) have played an important role in the treatment of metastatic CRC. However, the therapeutic response of anti-EGFR monoclonal antibodies is limited due to multiple resistance mechanisms. With the discovery of new functions for gold nanoparticles (AuNPs), we hypothesize that cetuximab-conjugated AuNPs (cetuximab-AuNPs) will not only improve the cytotoxicity for cancer cells, but also introduce expression change of the related biomarkers on cancer cell surface. In this contribution, we investigated the size-dependent cytotoxicity of cetuximab-AuNPs to CRC cell line (HT-29), while also monitored the expression of cell surface biomarkers in response to treatment with cetuximab and cetuximab-AuNPs. AuNPs with the size of 60 nm showed the highest impact for cell cytotoxicity, which was tested by cell counting kit-8 (CCK-8) assay. Three cell surface biomarkers including epithelial cell adhesion molecule (EpCAM), melanoma cell adhesion molecule (MCAM), and human epidermal growth factor receptor-3 (HER-3) were found to be expressed at higher heterogeneity when cetuximab was conjugated to AuNPs. Both surface-enhanced Raman scattering/spectroscopy (SERS) and flow cytometry demonstrated the correlation of cell surface biomarkers in response to the drug treatment. We thus believe this study provides powerful potential for drug-conjugated AuNPs to enhance cancer prognosis and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, gold nanoparticles have been used to effectively deliver various anti-CRC therapies to tumor cells, including chemotherapy drugs and anti-EGFR inhibitors, resulting in enhanced anticancer drug efficacy [110,111,112].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering
Nie, S., & Emory, S. R. (1997) · Science · doi:10.1126/science.275.5303.1102 · Cited by 10,238
Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions
FRENS, G. (1973) · Nature Physical Science · doi:10.1038/physci241020a0 · Cited by 8,336
Lewinski, N., Colvin, V., & Drezek, R. (2008) · Small · doi:10.1002/smll.200700595 · Cited by 2,810
Nanoparticle-mediated cellular response is size-dependent
Jiang, W., Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.30 · Cited by 2,776
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323
Nanoscale Forces and Their Uses in Self‐Assembly
Bishop, K. J. M., Wilmer, C. E., Soh, S., & Grzybowski, B. A. (2009) · Small · doi:10.1002/smll.200900358 · Cited by 1,521
Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles
Foroozandeh, P., & Aziz, A. A. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2728-6 · Cited by 1,377
Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer
Singh, P., Pandit, S., Mokkapati, V. R. S. S., Garg, A., Ravikumar, V., & Mijakovic, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071979 · Cited by 1,038
Epigenetic and genetic features of 24 colon cancer cell lines
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.35 · Cited by 910
Park, J.-W., & Shumaker-Parry, J. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4097384 · Cited by 708
Stockert, J. C., Blázquez-Castro, A., Cañete, M., Horobin, R. W., & Villanueva, Á. (2012) · Acta Histochemica · doi:10.1016/j.acthis.2012.01.006 · Cited by 661
Zhang, X., Servos, M. R., & Liu, J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3014055 · Cited by 593
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Gold nanoparticles for cancer radiotherapy: a review
Haume, K., Rosa, S., Grellet, S., Śmiałek, M. A., Butterworth, K. T., Solov’yov, A. V., Prise, K. M., Golding, J., & Mason, N. J. (2016) · Cancer Nanotechnology · doi:10.1186/s12645-016-0021-x · Cited by 445
A comparison of TEM and DLS methods to characterize size distribution of ceramic nanoparticles
Souza, T. G. F., Ciminelli, V. S. T., & Mohallem, N. D. S. (2016) · Journal of Physics: Conference Series · doi:10.1088/1742-6596/733/1/012039 · Cited by 442
Cai, L., Qin, X., Xu, Z., Song, Y., Jiang, H., Wu, Y., Ruan, H., & Chen, J. (2019) · ACS Omega · doi:10.1021/acsomega.9b01142 · Cited by 401
Piella, J., Bastús, N. G., & Puntes, V. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00575 · Cited by 382
Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, C. R., Bhattacharya, R., Wang, E., Katarya, A., Lau, J. S., Dutta, S., Muders, M., Wang, S., Buhrow, S. A., Safgren, S. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6102 · Cited by 371
A direct comparison of experimental methods to measure dimensions of synthetic nanoparticles
Eaton, P., Quaresma, P., Soares, C., Neves, C., de Almeida, M. P., Pereira, E., & West, P. (2017) · Ultramicroscopy · doi:10.1016/j.ultramic.2017.07.001 · Cited by 364
Experimental Considerations on The Cytotoxicity of Nanoparticles
Kong, B., Seog, J. H., Graham, L. M., & Lee, S. B. (2011) · Nanomedicine · doi:10.2217/nnm.11.77 · Cited by 357
Liu, X., Chen, Y., Li, H., Huang, N., Jin, Q., Ren, K., & Ji, J. (2013) · ACS Nano · doi:10.1021/nn402201w · Cited by 356
Wang, S.-H., Lee, C.-W., Chiou, A., & Wei, P.-K. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-33 · Cited by 286
Effect of Gold Nanoparticle Size on Their Properties as Contrast Agents for Computed Tomography
Dong, Y. C., Hajfathalian, M., Maidment, P. S. N., Hsu, J. C., Naha, P. C., Si-Mohamed, S., Breuilly, M., Kim, J., Chhour, P., Douek, P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50332-8 · Cited by 257
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 227
Mahato, K., Nagpal, S., Shah, M. A., Srivastava, A., Maurya, P. K., Roy, S., Jaiswal, A., Singh, R., & Chandra, P. (2019) · 3 Biotech · doi:10.1007/s13205-019-1577-z · Cited by 194
Wang, J., Koo, K. M., Wang, Y., & Trau, M. (2019) · Advanced Science · doi:10.1002/advs.201900730 · Cited by 192
Self-citationEGFR Signaling in Colorectal Carcinoma
Krasinskas, A. M. (2011) · Pathology Research International · doi:10.4061/2011/932932 · Cited by 184
Yue, J., Feliciano, T. J., Li, W., Lee, A., & Odom, T. W. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00252 · Cited by 181
Self‐Assembled SERS Substrates with Tunable Surface Plasmon Resonances
Lee, W., Lee, S. Y., Briber, R. M., & Rabin, O. (2011) · Advanced Functional Materials · doi:10.1002/adfm.201101218 · Cited by 175
Rational design and synthesis of SERS labels
Wang, Y., & Schlücker, S. (2013) · The Analyst · doi:10.1039/c3an36866a · Cited by 159
Self-citationNanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis
Bhattacharyya, S., Bhattacharya, R., Curley, S., McNiven, M. A., & Mukherjee, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006507107 · Cited by 141
Banu, H., Sethi, D. K., Edgar, A., Sheriff, A., Rayees, N., Renuka, N., Faheem, S. M., Premkumar, K., & Vasanthakumar, G. (2015) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2015.05.008 · Cited by 139
Near‐Field Enhanced Plasmonic‐Magnetic Bifunctional Nanotubes for Single Cell Bioanalysis
Xu, X., Li, H., Hasan, D., Ruoff, R. S., Wang, A. X., & Fan, D. L. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201203822 · Cited by 136
Surface Plasmon Resonance of Nanoparticles and Applications in Imaging
Ammari, H., Deng, Y., & Millien, P. (2015) · Archive for Rational Mechanics and Analysis · doi:10.1007/s00205-015-0928-0 · Cited by 128
Characterising the phenotypic evolution of circulating tumour cells during treatment
Tsao, S. C., Wang, J., Wang, Y., Behren, A., Cebon, J. S., & Trau, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03725-8 · Cited by 122
Self-citationLi, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · cited 2×
“Although the use of cetuximab has greatly improved the clinical outcomes of metastatic CRC, the discovery of resistance to anti-EGFR monoclonal antibodies stimulated interest in the study of drug resistance, including abnormal molecules in the EGFR pathway, abnormal activations between the paralleled pathways, and oth…”
BackgroundSelf-citationQian, Y., Qiu, M., Wu, Q., Tian, Y., Zhang, Y., Gu, N., Li, S., Xu, L., & Yin, R. H. (2014) · Scientific Reports · doi:10.1038/srep07490 · Cited by 118
Zhang, W., Jiang, L., Diefenbach, R. J., Campbell, D. H., Walsh, B. J., Packer, N. H., & Wang, Y. (2020) · ACS Sensors · doi:10.1021/acssensors.9b02377 · Cited by 118
Self-citationMutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
Knickelbein, K., & Zhang, L. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.10.002 · Cited by 117
Karmani, L., Labar, D., Valembois, V., Bouchat, V., Nagaswaran, P. G., Bol, A., Gillart, J., Levêque, P., Bouzin, C., Bonifazi, D., et al. (2013) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1539 · Cited by 106
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Molecular targeted therapy of BRAF-mutant colorectal cancer
Ducreux, M., Chamseddine, A., Laurent-Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samallin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 100
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51981-5 · Cited by 82
Liu, Y., Lyu, N., Rajendran, V. K., Piper, J. A., Rodger, A., & Wang, Y. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04183 · Cited by 77
Self-citationZhao, X., Pan, J., Li, W., Yang, W., Qin, L., & Pan, Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s176928 · Cited by 75
Agabeigi, R., Rasta, S. H., Rahmati-Yamchi, M., Salehi, R., & Alizadeh, E. (2020) · Nanoscale Research Letters · doi:10.1186/s11671-020-3295-1 · Cited by 75
Gold nanoparticles in chemo-, immuno-, and combined therapy: review [Invited]
Dykman, L. A., & Khlebtsov, N. G. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.003152 · Cited by 75
Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model
Kao, H.-W., Lin, Y.-Y., Chen, C., Chi, K., Tien, D., Hsia, C.-C., Lin, W., Chen, F., Lin, M.-H., & Wang, H. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/29/295102 · Cited by 74
Cytotoxicity and cellular uptake of different sized gold nanoparticles in ovarian cancer cells
Kumar, D., Mutreja, I., Chitcholtan, K., & Sykes, P. H. (2017) · Nanotechnology · doi:10.1088/1361-6528/aa935e · Cited by 72
Zhang, X., Gouriye, T., Göeken, K. L., et al. (2013) · The Journal of Physical Chemistry C · doi:10.1021/jp403946x · Cited by 70
Antibody-functionalized Gold Nanoparticles As tumor-targeting Radiosensitizers for Proton Therapy
Li, S., Bouchy, S., Penninckx, S., Marega, R., Fichera, O., Gallez, B., Feron, O., Martinive, P., Heuskin, A.-C., Michiels, C., et al. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0161 · Cited by 65
LIU, D., Sun, J., Zhu, J., Zhou, H., Zhang, X., & Zhang, Y. (2014) · Oncology Letters · doi:10.3892/ol.2014.1907 · Cited by 64
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Okada, Y., Kimura, T., Nakagawa, T., Okamoto, K., Fukuya, A., Goji, T., Fujimoto, S., Sogabe, M., Miyamoto, H., Muguruma, N., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0383 · Cited by 62
Cui, L., Her, S., Dunne, M., Borst, G. R., De Souza, R., Bristow, R. G., Jaffray, D. A., & Allen, C. (2017) · Radiation Research · doi:10.1667/rr14578.1 · Cited by 58
Christensen, T. D., Jensen, S. G., Larsen, F. O., & Nielsen, D. L. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.09.009 · Cited by 57
SERS Nanotags and Their Applications in Biosensing and Bioimaging
Zhang, W., Jiang, L., Piper, J. A., & Wang, Y. (2018) · Journal of Analysis and Testing · doi:10.1007/s41664-018-0053-9 · Cited by 52
Self-citationGoldberg, R. M., Montagut, C., Wainberg, Z. A., Ronga, P., Audhuy, F., Taieb, J., Stintzing, S., Siena, S., & Santini, D. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000353 · Cited by 50
Han, S., Zong, S., Shi, Q. W., Li, H., Liu, S., Yang, W., Li, W., & Hou, F. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.025 · Cited by 50
Liu, D., Du, L., Chen, D., Ye, Z., Duan, H., Tu, T., Feng, J., Yang, Y., Chen, Q., & Yan, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9930 · Cited by 49
Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
Bertotti, A., & Sassi, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0848 · Cited by 45 · cited 1×
“It was reported that aberrant activation of alternative receptors, such as human epidermal growth factor receptor 2 (HER2) and human epidermal growth factor receptor 3 (HER3) overexpression, is one of the molecular mechanisms for the resistance to anti-EGFR treatment [12,13].”
BackgroundKotcherlakota, R., Vydiam, K., Srinivasan, D. J., Mukherjee, S., Roy, A., Kuncha, M., Rao, T. N., Sistla, R., Gopal, V., & Patra, C. R. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00006 · Cited by 43
MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM
Kodama, T., Marian, T. A., Lee, H., Kodama, M., Li, J., Parmacek, M. S., Jenkins, N. A., Copeland, N. G., & Wei, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910413116 · Cited by 38
de Andrade, L. M., Martins, E. M. N., Versiani, A. F., et al. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.110203 · Cited by 37
Groysbeck, N., Stoessel, A., Donzeau, M., Silva, E. C. D., Lehmann, M., Strub, J., Cianférani, S., Dembélé, K., & Zuber, G. (2019) · Nanotechnology · doi:10.1088/1361-6528/aaff0a · Cited by 33
Wang, J., Anderson, W., Li, J., Lin, L. L., Wang, Y., & Trau, M. (2018) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.11.035 · Cited by 31
Self-citationGold Nanorod Bioconjugates for Active Tumor Targeting and Photothermal Therapy
Green, H. N., Martyshkin, D. V., Rodenburg, C. M., Rosenthal, E. L., & Mirov, S. (2011) · Journal of Nanotechnology · doi:10.1155/2011/631753 · Cited by 30
Yao, C., Rudnitzki, F., Hüttmann, G., et al. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140620 · Cited by 30
Gold Nanoparticles Regulate Tight Junctions and Improve Cetuximab Effect in Colon Cancer Cells
Leve, F., Bonfim, D. P., Fontes, G. N., & Morgado‐Díaz, J. A. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0023 · Cited by 29
Chemosensitization of Cancer Cells via Gold Nanoparticle‐Induced Cell Cycle Regulation
Mackey, M. A., & El‐Sayed, M. A. (2013) · Photochemistry and Photobiology · doi:10.1111/php.12226 · Cited by 29
Integrating anti-EGFR therapies in metastatic colorectal cancer.
Haraldsdóttir, S., & Bekaii‐Saab, T. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.028 · Cited by 28
Li, J., Lin, S., Chen, H.-Q., Liang, L., Mo, X., Lai, H., Zhang, J., Xu, J., Gao, B.-Q., Feng, Y., et al. (2019) · BMC Clinical Pathology · doi:10.1186/s12907-019-0085-8 · Cited by 27
Lédel, F., Stenstedt, K., Hallström, M., Ragnhammar, P., & Edler, D. (2015) · Acta Oncologica · doi:10.3109/0284186x.2014.983654 · Cited by 23
Yan, Q., Guo, K., Guan, F., Shan, F., Sun, L., Zhang, K., Shen, F., Shen, M., & Ruan, S. (2018) · Medicine · doi:10.1097/md.0000000000012317 · Cited by 18
Gal, O., Mizrachi, A., & Popovtzer, A. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.07.1593 · Cited by 2
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For instance, gold nanoparticles have been used to effectively deliver various anti-CRC therapies to tumor cells, including chemotherapy drugs and anti-EGFR inhibitors, resulting in enhanced anticancer drug efficacy [110–112].”
Metadata
- Authors
- El Hallal, R., Lyu, N., & Wang, Y.
- Affiliations
- Department of Molecular Sciences, Macquarie University, Sydney, NSW 2109, Australia
- Macquarie University (AU)
- Corresponding author
- Wang, Yuling
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-01-22
- Volume
- 26
- Issue
- 3
- Pages
- 567
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7865832
- OpenAlex
- W3121829375
- Cited by
- 51
- References
- 76
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 11 · 2023: 11 · 2022: 13 · 2021: 2
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Institute NSW
- Topics
- Physical Sciences › Materials Science › Electronic, Optical and Magnetic Materials › Gold and Silver Nanoparticles Synthesis and Applications
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- cetuximab, gold nanoparticles, colorectal cancer, epidermal growth factor receptor, cytotoxicity, nanoparticle size, cell surface markers, EpCAM, CD146, HER3, HT-29 cells, surface-enhanced Raman scattering, targeted cancer therapy
- MeSH terms
- Cetuximab, Epithelial Cell Adhesion Molecule, Antineoplastic Agents, Immunological, Cell Survival, Gold, Humans, Particle Size, Phenotype, Spectrum Analysis, Raman, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, HT29 Cells, Receptor, ErbB-3, CD146 Antigen, Metal Nanoparticles, Nanoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.